Article Contents ::
- 1 Details About Generic Salt :: Anistrep
- 2 Main Medicine Class:: Thrombolytic enzyme
- 3 (uh-NISS-truh-place) Eminase Class: Thrombolytic enzyme
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Anistrep
Main Medicine Class:: Thrombolytic enzyme
(uh-NISS-truh-place)
Eminase
Class: Thrombolytic enzyme
Drugs Class ::
Action Aids in dissolution of blood clots.
Indications for Drugs ::
Indications Lysis of obstructing coronary thrombi for management of acute MI.
Drug Dose ::
Route/Dosage
ADULTS: IV 30 U over 2 to 5 min into IV line or vein.
Contraindication ::
Contraindications Hypersensitivity to streptokinase; active internal bleeding; history of cerebrovascular accident; recent (within 2 mo) intracranial or intraspinal surgery or trauma; intracranial neoplasm; arteriovenous malformation or aneurysm; known bleeding diathesis; uncontrolled hypertension.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Hypersensitivity: Rarely anaphylactic and anaphylactoid reactions (with bronchospasm or angioedema) may occur. Readministration: Because of formation of antistreptokinase antibody, anistreplase may not be effective if administered > 5 day to 6 mo after prior anistreplase or streptokinase therapy or after streptococcal infection.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Arrhythmia and conduction disorders; hypotension. HEMA: Bleeding at puncture site, nonpuncture-site hematoma; hematuria; hemoptysis; GI hemorrhage; intracranial bleeding; mouth and gum hemorrhage; epistaxis; ocular hemorrhage; nonspecific hemorrhage.
Drug Mode of Action ::
Action Aids in dissolution of blood clots.
Drug Interactions ::
Interactions
Anticoagulants (eg, heparin, warfarin) and antiplatelet agents (eg, aspirin, dipyridamole): May increase risk of bleeding. INCOMPATIBILITIES: Do not add to any infusion fluids. Do not add other medications to vial or syringe containing anistreplase.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Identify factors that may contribute to bleeding risk, including baseline coagulation and fibrinolytic activity test results.
- Determine if and when previous fibrinolytic therapy was administered.
- Have epinephrine and emergency treatment provisions available during administration of anistreplase.
- Avoid nonessential handling of patient during anistreplase therapy.
- If arterial puncture is necessary after administration of anistreplase, it is preferable to use upper extremity vessel that is accessible to manual compression. Apply pressure dressing; check puncture site frequently for evidence of bleeding. Control minor bleeding with manual pressure.
- Remember that allergic-type reactions may occur in milder forms up to 1 to 2 wk after therapy.
- Evaluate data from cardiac monitoring, and report any arrhythmias.
- Monitor diligently for signs or symptoms of internal or surface bleeding. Remember that lab values for coagulation tests and measurements of fibrinolytic activity after anistreplase therapy may be unreliable.
- Monitor vital signs, especially BP and pulse, because severe hypotension may occur.
Drug Storage/Management ::
Administration/Storage
- Reconstitute powder with 5 ml of Sterile Water for Injection. Do not shake vial during reconstitution; try to minimize foaming. Do not further dilute reconstituted anistreplase.
- Administer 30 U of anistreplase by IV injection over 2 to 5 min.
- Store lyophilized anistreplase under refrigeration.
- Discard any reconstituted anistreplase not administered within 30 min of reconstitution.
Drug Notes ::
Patient/Family Education
- Explain to patient the need for bedrest and minimal handling of patient.
- Instruct patient to report the following symptoms to physician: Bruising, bleeding and hypersensitivity reactions (eg, urticaria, flushing, itching, rashes).
- Caution patient to avoid sudden position changes to prevent orthostatic hypotension.